ODM-209
- Generic Name
- ODM-209
Safety and Pharmacokinetics of ODM-209
Phase 1
Completed
- Conditions
- Metastatic Breast CancerCastration-resistant Prostate CancerProstate Cancer MetastaticAdvanced Breast Cancer
- Interventions
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 38
- Registration Number
- NCT03878823
- Locations
- 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland
🇫🇷Institut Gustave Roussy, Villejuif, France
🇩🇰Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath